Literature DB >> 227234

Streptozotocin treatment of a pancreatic tumour producing VIP and gastrin associated with Verner-Morrison syndrome.

K Oberg, H Boström, J Fahrenkrug, J F Dymling, O B Shaffalitsky de Muckadell, G Lundqvist.   

Abstract

A 57-year-old male patient with metastasizing non-beta islet cell carcinoma of the pancreas is described. Both gastrin and VIP levels were elevated and the patient suffered from a syndrome of pancreatic cholera and hyperacidity. The tumour contained gastrin and VIP as demonstrated by immunofluorescence. The patient also had a history of familial renal stone formation and parathyroid nodular hyperplasia. Resection of pancreatic tumour in 1973 resulted in four years without symptoms. In 1977 definite signs of multiple hepatic metastases appeared. These signs disappeared after streptozotocin given in a dosage of 2 g three times at weekly intervals. The patient had remained well for 20 months after this treatment. The causative agents for the clinical syndrome in this case are discussed in view of circulating hormone levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227234     DOI: 10.1111/j.0954-6820.1979.tb13499.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome.

Authors:  Tatsunosuke Ichimura; Satoshi Kondo; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas).

Authors:  R G Long; M G Bryant; S J Mitchell; T E Adrian; J M Polak; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

3.  Mixed pancreatic apudoma with symptoms of excess vasoactive intestinal polypeptide and insulin: improvement of diarrhoea with metoclopramide.

Authors:  R G Long; M G Bryant; P M Yuille; J M Polak; S R Bloom
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.